Molecular Stratification of CKD
Anna Reznichenko(AstraZeneca (Sweden)), Matthias Kretzler(University of Michigan), Viji Nair(University of Michigan), Shawn S. Badal(Gilead Sciences (United States)), Julie Williams(UK Dementia Research Institute), Mark Tomilo(University of Michigan), Sven Moosmang(Boehringer Ingelheim (Germany)), Matthew D. Breyer(Johnson & Johnson (United States)), Kevin L. Duffin(Eli Lilly (United States)), James Conway(AstraZeneca (United States)), Tim Slidel(AstraZeneca (United Kingdom)), Johnna D. Wesley(Novo Nordisk (United States)), Wenjun Ju(Xuzhou Medical College), Ratan V. Bhat(AstraZeneca (Sweden)), Uptal D. Patel(Medical University of Vienna), Anil Karihaloo(Novo Nordisk (United States)), Sean Eddy(Michigan Medicine), John T. Liles(Gilead Sciences (United States)), Carol P. Moreno Quinn(AstraZeneca (United Kingdom)), Maria Chiara Magnone(Janssen (Belgium))
Cited by 0
Related Papers
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
|The Lancet|2017|923
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840
Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
|Kidney International|2020|724
Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology
|Molecular Psychiatry|2013|440